Artemether-lumefantrine (COA566)
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Uncomplicated Falciparum Malaria
Conditions
Acute Uncomplicated Falciparum Malaria
Trial Timeline
Oct 1, 2012 → Jul 1, 2014
NCT ID
NCT01619878About Artemether-lumefantrine (COA566)
Artemether-lumefantrine (COA566) is a phase 2/3 stage product being developed by Novartis for Acute Uncomplicated Falciparum Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT01619878. Target conditions include Acute Uncomplicated Falciparum Malaria.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01619878 | Phase 2/3 | Completed |
Competing Products
20 competing products in Acute Uncomplicated Falciparum Malaria